Skip to main content

Table 2 Clinical characteristics according to IDH mutational status in gliomas

From: The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas

Clinical characteristic   N = 811 IDH1-Mutated IDH2-Mutated IDH1/IDH2-Wild-type P (IDH1-Mutated VS IDH1/IDH2- Wild-type) P (IDH2-Mutated VS IDH1/IDH2- Wild-type) P (IDH1-Mutated VS IDH2-Mutated)
    No. (%) No. (%) No. (%)    
Age, years <45 423 285 (67.4) 13 (3.1) 125 (29.5) <0.001 <0.05 0.456
  ≥45 388 163 (42.0) 5 (1.3) 220 (56.7)    
Median age, years    39.1 37.3 45.0 <0.001 <0.05 0.456
Range    17.0–66.0 26.0–56.0 9.0–81.0    
Gender Male 495 265 (53.5) 11 (2.2) 219 (44.2) 0.113 0.801 0.824
  Female 316 186 (58.9) 7 (2.2) 123 (38.9)    
WHO Grade II + III 577 403 (69.8) 16 (2.8) 158 (27.4) <0.001 <0.001 0.883
  IV 234 45 (19.2) 2 (0.9) 187 (79.9)    
KPS score <80 74 26 (35.1) 2 (2.7) 46 (62.2) <0.001 0.376 0.514
  ≥80 253 173 (68.4) 7 (2.8) 73 (28.8)    
  NA 483 248 9 226    
Histologic type Oligodendroglioma 76 57 (75.0) 4 (5.3) 15 (19.7) <0.001 <0.001 0.218
  Oligoastrocytoma 269 194 (72.1) 10 (3.7) 65 (24.2)    
  Astrocytoma 437 181 (41.4) 3 (0.7) 253 (57.9)    
  sGBM 29 16 (55.2) 1 (3.4) 12 (41.4)    
Laterality Left 380 211 (55.5) 9 (2.4) 160 (42.1) <0.05 0.891 0.985
  Right 366 203 (55.5) 8 (2.2) 155 (42.3)    
  Midline 53 33 (62.3) 1 (1.9) 19 (35.8)    
  NA 12 1 0 11